Athersys begins Phase I trial for ATHX-105 for treatment of obesity

News | 07. 25. 2007


Athersys, Inc., a wholly owned subsidiary of BTHC VI (OTC Bulletin Board: BVIC), announced today that it has initiated a Phase I clinical trial in the United Kingdom for ATHX-105, the company’s oral, selective 5HT2c receptor agonist for treating obesity.